Thrombotic microangiopathy: What not to learn from a meta-analysis

Nature Reviews Nephrology

Volumn 5, Issue 4, 2009, Pages 186-188

  Noris, Marina ^a   Remuzzi, Giuseppe ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; MEMBRANE COFACTOR PROTEIN; RITUXIMAB; STEROID; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

CLINICAL TRIAL; HEMOLYTIC UREMIC SYNDROME; HEMORRHAGIC COLITIS; HUMAN; META ANALYSIS; MICROANGIOPATHY; PATHOGENESIS; PLASMA TRANSFUSION; PLASMAPHERESIS; PRIORITY JOURNAL; SHORT SURVEY; SYSTEMATIC REVIEW; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; GENETICS; NOTE; PATIENT SELECTION;

HEMOLYTIC-UREMIC SYNDROME; HUMANS; META-ANALYSIS AS TOPIC; PATIENT SELECTION; PLASMA EXCHANGE; PURPURA, THROMBOTIC THROMBOCYTOPENIC; TREATMENT OUTCOME;

EID: 67049161222     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2009.28     Document Type: Short Survey

References (7)

1. Ruggenenti, P., noris, M. & Remuzzi, G. Thrombotic microangiopathies. in Therapy in Nephrology and Hypertension: A Companion to Brenner and Rector's The Kidney 3rd edn (ed. Wilcox, C. S.) 294-312 (saunders, Philadelphia, 2008).
2. Michael, M., Elliott, E. J., Craig, J. C., Ridley, G. & Hodson, e. M. interventions for hemolytic uremic Syndrome and thrombotic thrombocytopenic purpura: a Systematic review of randomized controlled trials. Am. J. Kidney Dis. 53, 259-272 (2008).
3. Ruggenenti, P., Galbusera, M., Cornejo, R. P., Bellavita, P. & Remuzzi, G. Thrombotic thrombocytopenic purpura: evidence that infusion rather than removal of plasma induces remission of the disease. Am. J. Kidney Dis. 21, 314-318 (1993).
4. Davin, J. C., Strain, L. & Goodship, T. H. Plasma therapy in atypical haemolytic uremic Syndrome: lessons from a family With a factor H mutation. Pediatr. Nephrol. 23, 1517-1521 (2008).
5. Nathanson, S., Frémeaux-Bacchi, V. & Deschênes, G. Successful plasma therapy in the hemolytic uremic Syndrome With factor H deficiency. Pediatr. Nephrol. 16, 554-556 (2001).
6. Caprioli, J. et al. Genetics of HUs: the impact of MCP, CFH and iF mutations on clinical presentation, response to treatment, and outcome. Blood 108, 1267-1279 (2006).
7. Sellier-Leclerc, A. L, Fremeaux-Bacchi, V., Dragon-Durey, M. A., Macher, M. A. & niaudet, P. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic Syndrome. J. Am. Soc. Nephrol. 18, 2390-2400 (2007).